Reneo Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Arrangements
During the three months ended June 30, 2024, certain of our directors and/or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.
| Type of Trading Arrangement | |||||
|---|---|---|---|---|---|
| Name and Position · Action · Adoption/ TerminationDate · Rule 10b5-1* · Non-Rule 10b5-1** · Total Shares of Common Stock to be Sold · Expiration Date | |||||
| Jennifer P. Lam | Termination | May 29, 2024 | X | 39,600 | September 25, 2025 |
| Ashley F. Hall, J.D. | Termination | June 3, 2024 | X | 71,562 | September 17, 2025 |
| Alejandro Dorenbaum, M.D. | Termination | June 8, 2024 | X | 121,927 | September 18, 2025 |
- Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.